Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL). Its product candidates includes include EP-3101, (bendamustine ready-to-dilute) for CLL and indolent B-cell NHL; EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 (pemetrexed) for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EGRX
CUSIPN/A
Phone201-326-5300
Debt
Debt-to-Equity Ratio0.22
Current Ratio4.22
Quick Ratio4.09
Price-To-Earnings
Trailing P/E Ratio23.86
Forward P/E Ratio37.40
P/E GrowthN/A
Sales & Book Value
Annual Sales$236.71 million
Price / Sales5.12
Cash Flow$3.9714 per share
Price / Cash20.25
Book Value$12.01 per share
Price / Book6.70
Profitability
EPS (Most Recent Fiscal Year)$3.37
Net Income$51.94 million
Net Margins13.81%
Return on Equity19.71%
Return on Assets13.28%
Miscellaneous
Employees108
Outstanding Shares15,060,000
Market Cap$1.18 billion
Eagle Pharmaceuticals (NASDAQ:EGRX) Frequently Asked Questions
What is Eagle Pharmaceuticals' stock symbol?
Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."
How will Eagle Pharmaceuticals' stock buyback program work?
Eagle Pharmaceuticals declared that its board has approved a stock repurchase program on Thursday, August 10th 2017, which permits the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to reacquire up to 13.3% of its stock through open market purchases. Stock repurchase programs are often an indication that the company's management believes its shares are undervalued.
How were Eagle Pharmaceuticals' earnings last quarter?
Eagle Pharmaceuticals Inc (NASDAQ:EGRX) announced its quarterly earnings data on Tuesday, August, 7th. The specialty pharmaceutical company reported $0.95 EPS for the quarter, beating the Zacks' consensus estimate of $0.80 by $0.15. The specialty pharmaceutical company had revenue of $59.30 million for the quarter, compared to analyst estimates of $51.78 million. Eagle Pharmaceuticals had a return on equity of 19.71% and a net margin of 13.81%. View Eagle Pharmaceuticals' Earnings History.
When is Eagle Pharmaceuticals' next earnings date?
What price target have analysts set for EGRX?
4 brokers have issued 12-month price targets for Eagle Pharmaceuticals' stock. Their predictions range from $54.00 to $88.00. On average, they anticipate Eagle Pharmaceuticals' stock price to reach $76.75 in the next year. This suggests that the stock has a possible downside of 4.6%. View Analyst Price Targets for Eagle Pharmaceuticals.
What is the consensus analysts' recommendation for Eagle Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eagle Pharmaceuticals.
What are Wall Street analysts saying about Eagle Pharmaceuticals stock?
Here are some recent quotes from research analysts about Eagle Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. " (7/11/2018)
- 2. Mizuho analysts commented, "We don’t yet have this product in our model, and don’t expect it to be a meaningful revenue generator because Treanda powder currently has minimal market share. Big bag" may provide insurance if Eagle fails to bar Treanda generics from the market via its Orphan Drug litigation, in our view. The Fulvestrant clinical trial is fully enrolled, and data are expected in the fall. Additionally, the FDA accepted Eagle’s Vasostrict ANDA, which Endo indicated would be subject to the full litigation pathway. We have no estimates for the Ryanodex program for nerve agent exposure and note that Eagle did not provide an update on its drug- induced hyperthermia program, which we believe could get dropped. We summarize 1Q:18 performance below and reiterate our Underperform rating." (5/10/2018)
Who are some of Eagle Pharmaceuticals' key competitors?
Some companies that are related to Eagle Pharmaceuticals include Agios Pharmaceuticals (AGIO), Taro Pharmaceutical Industries (TARO), Ultragenyx Pharmaceutical (RARE), HUTCHISON CHINA/S (HCM), GW Pharmaceuticals PLC- (GWPH), Madrigal Pharmaceuticals (MDGL), Endo International (ENDP), Horizon Pharma (HZNP), Evotec (EVTCY), Opko Health (OPK), Akcea Therapeutics (AKCA), Blueprint Medicines (BPMC), Intercept Pharmaceuticals (ICPT), Array Biopharma (ARRY) and Ascendis Pharma A/S (ASND).
Who are Eagle Pharmaceuticals' key executives?
Eagle Pharmaceuticals' management team includes the folowing people:
- Mr. Scott L. Tarriff, CEO & Director (Age 58)
- Mr. David M. Pernock, Pres & Chief Commercial Officer (Age 65)
- Mr. Pete A. Meyers, Chief Financial Officer (Age 48)
- Dr. Adrian Hepner, Exec. VP & Chief Medical Officer (Age 57)
- Mr. Daniel O'Connor, Exec. VP of Biologics and Corp. Devel. (Age 38)
Has Eagle Pharmaceuticals been receiving favorable news coverage?
News headlines about EGRX stock have been trending somewhat positive recently, Accern reports. The research group ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Eagle Pharmaceuticals earned a daily sentiment score of 0.14 on Accern's scale. They also assigned media stories about the specialty pharmaceutical company an impact score of 46.01 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Eagle Pharmaceuticals.
Who are Eagle Pharmaceuticals' major shareholders?
Eagle Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (12.74%), BlackRock Inc. (9.65%), Iridian Asset Management LLC CT (5.80%), Victory Capital Management Inc. (4.49%), LSV Asset Management (3.99%) and Rothschild Asset Management Inc. (2.75%). Company insiders that own Eagle Pharmaceuticals stock include David Pernock, Douglas L Braunstein, Pete A Meyers, Proquest Investments Iv, LP, Richard A Edlin, Sander A Flaum, Sander A Flaum, Steven B Ratoff and Steven L Krill. View Institutional Ownership Trends for Eagle Pharmaceuticals.
Which institutional investors are selling Eagle Pharmaceuticals stock?
EGRX stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., LSV Asset Management, Schwab Charles Investment Management Inc., FMR LLC, Royce & Associates LP, Globeflex Capital L P, Janus Henderson Group PLC and Brandes Investment Partners LP. View Insider Buying and Selling for Eagle Pharmaceuticals.
Which institutional investors are buying Eagle Pharmaceuticals stock?
EGRX stock was purchased by a variety of institutional investors in the last quarter, including Rothschild Asset Management Inc., BlackRock Inc., Chartwell Investment Partners LLC, Granite Investment Partners LLC, Sei Investments Co., Bank of America Corp DE, ClariVest Asset Management LLC and Engineers Gate Manager LP. Company insiders that have bought Eagle Pharmaceuticals stock in the last two years include David Pernock, Douglas L Braunstein, Pete A Meyers and Richard A Edlin. View Insider Buying and Selling for Eagle Pharmaceuticals.
How do I buy shares of Eagle Pharmaceuticals?
Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eagle Pharmaceuticals' stock price today?
One share of EGRX stock can currently be purchased for approximately $80.42.
How big of a company is Eagle Pharmaceuticals?
Eagle Pharmaceuticals has a market capitalization of $1.18 billion and generates $236.71 million in revenue each year. The specialty pharmaceutical company earns $51.94 million in net income (profit) each year or $3.37 on an earnings per share basis. Eagle Pharmaceuticals employs 108 workers across the globe.
How can I contact Eagle Pharmaceuticals?
Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]
MarketBeat Community Rating for Eagle Pharmaceuticals (NASDAQ EGRX)
MarketBeat's community ratings are surveys of what our community members think about Eagle Pharmaceuticals and other stocks. Vote "Outperform" if you believe EGRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EGRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
